484 Results (Page 2 of 20)
Brazil Markets Research Reports
Brazil Lymphoma Therapeutics Market Analysis
Brazil's Lymphoma Therapeutics Market was valued at $431.38 Mn in 2023 and is predicted to grow at a CAGR of 8.80 % from 2023 to 2030, to $778.51 Mn by 2030. The key drivers of this industry include an increasing incidence of lymphomas, robust pipeline products, growing geriatric population. The industry is primarily dominated by Bristol-Myers Squibb Company, Merck & Co., Novartis AG, Johnson & Johnson, GSK plc, and AstraZeneca plc among others.
Brazil Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
Brazil Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Brazil Adrenoleukodystrophy (ALD) drugs market.
Brazil COVID-19 Clinical Trials Market Analysis
This report presents a strategic analysis of the Brazil COVID-19 Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Brazil COVID-19 Clinical Trials Market, offering unmatched value, accuracy and expert insights.
Brazil Clinical Trials Support Service Market Analysis
This report presents a strategic analysis of the Brazil Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Brazil Clinical Trials Support Service Market, offering unmatched value, accuracy, and expert insights.
Brazil eHealth Market Analysis
This report presents a strategic analysis of the Brazil eHealth Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Brazil eHealth Market, offering unmatched value, accuracy and expert insights.
Brazil Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis
This report presents a strategic analysis of the Brazil Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Brazil Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy and expert insights.
Brazil Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Brazil Cough Hypersensitivity Syndrome Therapeutics Market was valued at $203 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $345 Mn by 2030. The primary factors propelling this industry involve the surge in the prevalence of Cough Hypersensitivity Syndrome, high unmet medical needs, and growing healthcare expenditure. The industry is primarily dominated by players such as Sanofi, Pfizer, Teva, Novartis, Johnson & Johnson, and GSK among others.
Brazil Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the Brazil Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Brazil Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
Brazil Advanced Therapy Medicinal Products (ATMPs) Market Analysis
This report presents a strategic analysis of the Brazil Advanced Therapy Medicinal Products (ATMPs) Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Brazil Advanced Therapy Medicinal Products (ATMPs) Market, offering unmatched value, accuracy, and expert insights.
Brazil Nutritional Supplements Market Analysis
By 2030, it is anticipated that the Brazil Nutrition and Supplements market will reach a value of $19.71 Bn from $9.54 Bn in 2022, growing at a CAGR of 9.5% during 2022-30. The market is primarily dominated by local players such as Herbarium, Biofield, and Bioenergy. The market for nutrition and supplements in Brazil is primarily driven by government initiatives, increasing consumer awareness for health and lifestyle and sports nutrition supplements. The Brazil nutrition and supplements market in Brazil is segmented by Type, Product, application, and Distribution Channel.
Brazil Electronic Health Records Market Analysis
Brazil's Electronic Health Record (EHR) market size was valued at $760 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 17.5% from 2022-30 and will reach $2760 Mn in 2030. Brazil's EHR market is growing as EHR can reduce the frequency of medical errors by improving the accuracy and clarity of medical records. The market is segmented by product, application, and end user. The key market players are Prosoft, Datasus, MedData, Allscripts, Cerner, and others.
Brazil Blockchain Technology in Healthcare Market Analysis
This report presents a strategic analysis of Brazil's Blockchain Technology in the Healthcare Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about Brazil's Blockchain Technology in the Healthcare Market, offering unmatched value, accuracy, and expert insights.
Brazil Biomaterials in Healthcare Market Analysis
Brazil's Biomaterials in Healthcare Market is expected to witness growth from $3.90 Bn in 2022 to $11.30 Bn in 2030 with a CAGR of 14.20% for the forecasted year 2022-30. The increasing incidence of periodontal disease, tooth decay, oral cancer, halitosis, and dental caries in Brazil is driving demand for biomaterials, which is expected to propel growth in the Brazilian biomaterial healthcare market. The market is segmented by type and by application. Some key players in this market include Baumer SA, Injex Surgical Industries, FGM Products Odontologicos, BASF SE, Johnson and Johnson, Medtronic, and Evonik Industries.
Brazil Central Nervous System (CNS) Therapeutics Market Analysis
The Brazil Central Nervous System (CNS)Therapeutics Market was valued at US $5.250 Bn in 2022 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030, to US $9.294 Bn by 2030. The key drivers of this industry include the increasing prevalence of CNS diseases, government initiatives, and new treatment options. The industry is primarily dominated by players such as Pfizer, Novartis, Biogen, AstraZeneca, Eli Lilly, Eurofarma, Merck, and Abbott among others.
Brazil Healthcare Reimbursement Market Analysis
This report presents a strategic analysis of the Brazil Healthcare Reimbursement Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Brazil Healthcare Reimbursement Market, offering unmatched value, accuracy, and expert insights.
Brazil Retail Pharmacy Market Analysis
Brazil's Retail Pharmacy Market is projected to grow from $25.97 Bn in 2022 to $47.70 Bn by 2030, registering a CAGR of 7.9% during the forecast period of 2022-30. The market is highly competitive, with a large number of players operating in the market, including local and international retail pharmacy chains, independent pharmacies, and online pharmacies. Drogaria Sao Paulo is one of the largest retail pharmacy chains in Brazil, with more than 1,300 stores across the country.
Brazil Electronic Records Management Solutions Market Analysis
Brazil's electronic records management solutions market size was valued at $xx Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by solution and deployment. Brazil’s Electronic Records Management Solutions market will grow the adoption of electronic records management systems (ERMS) is rising in the Brazilian healthcare industry, which is constrained by a number of market factors. The key market players are F2X Group, Grupo Mult, NEOCLOUD, QI Consultoria e Sistemas, SoftExpert, and others.
Brazil Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
Brazil Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
Brazil Adrenoleukodystrophy (ALD) Drugs Market Analysis
Brazil Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Global Adrenoleukodystrophy (ALD) drugs Market.
Brazil Pain Management Devices Market Analysis
This report presents a strategic analysis of the Brazil Pain Management Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Brazil Pain Management Devices Market, offering unmatched value, accuracy and expert insights.
Brazil Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis
Brazil Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis
Brazil's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $93 Mn in 2022 to $216 Mn in 2030 with a CAGR of 11.20% for the year 2022-30. The expansion of the PNH therapeutics market in Brazil is anticipated to be fueled by the creation of new technologies and treatment options for PNH. For instance, the recent approval of eculizumab (a monoclonal antibody that targets the complement system for the treatment of PNH) has dramatically improved patient outcomes and is probably going to lead to a rise in the demand for PNH medicines in Brazil. The market is segmented by therapy, diagnostic test, and distribution channel. Some key players in this market include Aché Laboratórios, Eurofarma, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen, CSL Behring, and Bioverativ.
Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis
Brazil Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.
Brazil Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
Brazil Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Brazil Chronic Myelogenous Leukemia Therapeutics Market Analysis
Brazil Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.